NCT05955261 2026-04-13
A Study of Venetoclax in Combination With Conventional Chemotherapy in Pediatric Patients With Acute Myeloid Leukemia
St. Jude Children's Research Hospital
Phase 2 Suspended
Clinical Trials
100 trialsNCT06660368 2026-04-01
BCL2i CLAG-M in R/R Acute Myeloid Leukemia
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Recruiting
NCT03150004 2026-03-30
Efficacy and Pharmacogenomics of Cladribine Based Salvage Chemotherapy in Patients With Relapse/Refractory and Secondary Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS)
Medical College of Wisconsin
Phase 2 Terminated
NCT03591510 2026-03-13
A Global Study of Midostaurin in Combination With Chemotherapy to Evaluate Safety, Efficacy and Pharmacokinetics in Newly Diagnosed Pediatric Patients With FLT3 Mutated AML
Novartis
Phase 2 Active not recruiting
NCT02523976 2026-02-11
Dasatinib Combined With Chemotherapy in Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia
Institute of Hematology & Blood Diseases Hospital, China
Phase 2 Completed
NCT03164057 2026-01-28
A Trial of Epigenetic Priming in Patients With Newly Diagnosed Acute Myeloid Leukemia
St. Jude Children's Research Hospital
Phase 2 Active not recruiting
NCT06451861 2025-11-17
Randomized Study of ABC-14 Regimen Compared With "3+7" Standard Induction Therapy or AB-14 for ND AML
Guangdong Provincial People's Hospital
Phase 2 Recruiting
NCT03860844 2025-09-09
ISAKIDS
Sanofi
Phase 2 Terminated
NCT04195945 2025-07-10
CPX-351 or CLAG-M Regimen for the Treatment of Acute Myeloid Leukemia or Other High-Grade Myeloid Neoplasms in Medically Less-Fit Patients
Fred Hutchinson Cancer Center
Phase 2 Active not recruiting
NCT04778410 2025-03-20
Study of Magrolimab Combinations in Participants With Myeloid Malignancies
Gilead Sciences
Phase 2 Terminated
NCT03839446 2025-02-20
Phase II Study of the Combination of Mitoxantrone, Etoposide and Gemtuzumab Ozogamicin (MEGO) for Patients With Acute Myeloid Leukemia Refractory to Initial Standard Induction Therapy
University of Pittsburgh
Phase 2 Completed
NCT02520011 2023-11-15
Alvocidib Biomarker-driven Phase 2 AML Study
Sumitomo Pharma America, Inc.
Phase 2 Terminated
NCT02583893 2023-10-10
Biomarkers in Predicting Treatment Response to Sirolimus and Chemotherapy in Patients With High-Risk Acute Myeloid Leukemia
Thomas Jefferson University
Phase 2 Completed
NCT00004197 2023-09-07
Vaccine Therapy Plus Sargramostim Following Chemotherapy in Previously Untreated Aggressive Non-Hodgkin's Lymphoma
University of Nebraska
Phase 2 Completed
NCT00005847 2023-06-22
Chemotherapy With or Without Biological Therapy in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy
Eastern Cooperative Oncology Group
Phase 2 Completed
NCT00003407 2023-02-02
Amifostine & High-Dose Combination Chemotherapy in Treating Patients With Acute ML or CML
Rush University Medical Center
Phase 2 Withdrawn
NCT02686593 2022-10-06
Clofarabine, Cytarabine and Mitoxantrone (CLAM) for Relapsed or Refractory AML
The University of Hong Kong
Phase 2 Completed
NCT01700946 2022-09-28
Therapy for Pediatric Relapsed or Refractory Precursor B-Cell Acute Lymphoblastic Leukemia and Lymphoma
St. Jude Children's Research Hospital
Phase 2 Completed
NCT00712582 2022-06-21
Therapy for Patients With Untreated Age-Adjusted International Prognostic Index Low-Intermediate Risk, High-Intermediate Risk, or High Risk Diffuse Large B Cell Lymphoma
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT00290511 2022-04-22
Rituximab, Fludarabine, Mitoxantrone, Dexamethasone (R-FND) Plus Zevalin for High-Risk Follicular Lymphoma
M.D. Anderson Cancer Center
Phase 2 Completed
NCT03012672 2022-03-08
Higher or Lower Dose Cladribine, Cytarabine, and Mitoxantrone in Treating Medically Less Fit Patients With Newly Diagnosed Acute Myeloid Leukemia or Myeloid Neoplasm
University of Washington
Phase 2 Completed
NCT00193479 2022-03-03
Combination Chemotherapy and Rituximab With Pegfilgrastim Followed by Rituximab, in Large B-Cell Non-Hodgkin's Lymphoma
SCRI Development Innovations, LLC
Phase 2 Completed
NCT01186640 2022-01-05
Combined Immunochemotherapy in Patients With T-Prolymphocytic Leukemia (T-PLL)
German CLL Study Group
Phase 2 Completed
NCT02756572 2021-11-08
Early Allogeneic Hematopoietic Cell Transplantation in Treating Patients With Relapsed or Refractory High-Grade Myeloid Neoplasms
University of Washington
Phase 2 Completed
NCT00003405 2021-10-14
Combination Chemotherapy Plus Biological Therapy in Treating Patients With Acute Myelogenous Leukemia
Rush University Medical Center
Phase 2 Withdrawn
NCT00901927 2020-04-03
Bendamustine, Mitoxantrone, and Rituximab (BMR) for Patients With Untreated High Risk Follicular Lymphoma
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT02733380 2020-04-01
Chidamide Combined With VDDT Regimen in the Relapse and Refractory Diffuse Large B Cell Lymphoma
Henan Cancer Hospital
Phase 2 Unknown
NCT00015951 2019-10-17
Bevacizumab, Cytarabine, and Mitoxantrone on Treating Patients With Hematologic Cancers
University of Maryland, Baltimore
Phase 2 Completed
NCT01204710 2019-09-20
A Study of Olaratumab (IMC-3G3) in Prostate Cancer
Eli Lilly and Company
Phase 2 Completed
NCT00169208 2019-08-28
Fludarabine, Mitoxantrone and Rituximab in Relapsed or Primary Failing Advanced Follicular Non-Hodgkin's Lymphoma
Lymphoma Study Association
Phase 2 Completed
NCT02535806 2019-08-13
Four Drug Reinduction With Bortezomib for Relapsed or Refractory ALL or LL in Children and Young Adults
Children's Mercy Hospital Kansas City
Phase 2 Terminated
NCT00254410 2019-05-01
FCM-R (Fludarabine, Cyclophosphamide, Mitoxantrone, Rituximab) in Previously Untreated Patients With Chronic Lymphocytic Leukemia (CLL) < 70 Years
M.D. Anderson Cancer Center
Phase 2 Completed
NCT02518750 2019-04-03
Re-Induction Therapy for Relapsed Pediatric T-Cell Acute Lymphoblastic Leukemia or Lymphoma
St. Jude Children's Research Hospital
Phase 2 Terminated
NCT00458848 2019-02-15
LAL0904
Gruppo Italiano Malattie EMatologiche dell'Adulto
Phase 2 Completed
NCT01133158 2018-11-01
R-BMD in Refractory or Relapsed Lymphoma, GELTAMO Clinical Trial
Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea
Phase 2 Completed
NCT00795002 2018-08-07
Alvocidib, Cytarabine, and Mitoxantrone in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
National Cancer Institute (NCI)
Phase 2 Completed
NCT00274963 2018-05-11
Bendamustine and Mitoxantrone in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
German CLL Study Group
Phase 2 Completed
NCT00278213 2018-05-11
Combination Chemotherapy Followed By Alemtuzumab in Treating Patients With Chronic Lymphocytic Leukemia or Prolymphocytic Leukemia
German CLL Study Group
Phase 2 Completed
NCT02462265 2018-04-18
Oshadi D & Oshadi R Combined With Salvage Chemotherapy for Relapsed Acute Myeloid Leukemia or Lymphoid Leukemia Patients
Oshadi Drug Administration
Phase 2 Suspended
NCT02419755 2018-03-07
Bortezomib and Vorinostat in Younger Patients With Refractory or Relapsed MLL Rearranged Hematologic Malignancies
St. Jude Children's Research Hospital
Phase 2 Terminated
NCT02198482 2018-02-28
Trial of Intensive Chemotherapy With or Without Volasertib in Patients With Newly Diagnosed High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)
University of Ulm
Phase 2 Terminated
NCT00268242 2018-02-22
Gemcitabine and Mitoxantrone in Treating Patients With Relapsed Acute Myeloid Leukemia
The Cleveland Clinic
Phase 2 Terminated
NCT00005985 2017-11-29
Filgrastim and Chemotherapy Followed by Peripheral Stem Cell Transplant in Treating Patients With Hodgkin's Lymphoma or Non-Hodgkin's Lymphoma
Masonic Cancer Center, University of Minnesota
Phase 2 Completed
NCT00005987 2017-11-29
Filgrastim Compared With Sargramostim Plus Chemotherapy, Peripheral Stem Cell Transplantation, and Interferon Alfa in Treating Patients With Multiple Myeloma
Masonic Cancer Center, University of Minnesota
Phase 2 Terminated
NCT00005998 2017-11-29
Peripheral Stem Cell Transplantation With Specially Treated Stem Cells in Treating Patients With Non-Hodgkin's Lymphoma or Hodgkin's Disease
Masonic Cancer Center, University of Minnesota
Phase 2 Withdrawn
NCT00477087 2017-11-29
Phase II GM-CSF Plus Mitoxantrone in Hormone Refractory Prostate Cancer
Stanford University
Phase 2 Terminated
NCT01349972 2017-07-31
Alvocidib, Cytarabine, and Mitoxantrone Hydrochloride or Cytarabine and Daunorubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
National Cancer Institute (NCI)
Phase 2 Completed
NCT00186875 2017-07-28
Therapy for Pediatric Relapsed or Refractory Acute Lymphoblastic Leukemia
St. Jude Children's Research Hospital
Phase 2 Completed
NCT00182741 2017-05-03
Calcitriol, Mitoxantrone, and Prednisone in Treating Patients With Metastatic Prostate Cancer
OHSU Knight Cancer Institute
Phase 2 Completed
NCT00017563 2017-04-28
Combination Chemotherapy Followed by Surgery in Treating Patients With Localized Prostate Cancer
OHSU Knight Cancer Institute
Phase 2 Completed